quickblock western blocking solution Search Results


antibodies against pcna  (Proteintech)
96
Proteintech antibodies against pcna
Antibodies Against Pcna, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quickblock+western+blocking+solution/10__1515_slash_oncologie___2024___0304-68-23-64?v=Proteintech
Average 96 stars, based on 1 article reviews
antibodies against pcna - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
cyclin b1  (Proteintech)
96
Proteintech cyclin b1
Figure 5: Genistein inhibits HCC cell proliferation in vitro. (A) Genistein suppresses HCC cell growth based on both concentration and exposure duration. (B) Genistein suppresses expression of the proliferation marker PCNA based on both concentration and exposure duration. (C) Genistein induces G2/M phase arrest in Huh7 and HepG2 cells. (D) Genistein induces G2/M phase arrest marker <t>Cyclin</t> <t>B1</t> in Huh7 and HepG2 cells (*p<0.05, **p<0.01, ***p<0.001).
Cyclin B1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quickblock+western+blocking+solution/10__1515_slash_oncologie___2024___0304-68-37-64?v=Proteintech
Average 96 stars, based on 1 article reviews
cyclin b1 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

Image Search Results


Figure 5: Genistein inhibits HCC cell proliferation in vitro. (A) Genistein suppresses HCC cell growth based on both concentration and exposure duration. (B) Genistein suppresses expression of the proliferation marker PCNA based on both concentration and exposure duration. (C) Genistein induces G2/M phase arrest in Huh7 and HepG2 cells. (D) Genistein induces G2/M phase arrest marker Cyclin B1 in Huh7 and HepG2 cells (*p<0.05, **p<0.01, ***p<0.001).

Journal: Oncologie

Article Title: Exploring the mechanism of genistein in treating hepatocellular carcinoma through network pharmacology and molecular docking

doi: 10.1515/oncologie-2024-0304

Figure Lengend Snippet: Figure 5: Genistein inhibits HCC cell proliferation in vitro. (A) Genistein suppresses HCC cell growth based on both concentration and exposure duration. (B) Genistein suppresses expression of the proliferation marker PCNA based on both concentration and exposure duration. (C) Genistein induces G2/M phase arrest in Huh7 and HepG2 cells. (D) Genistein induces G2/M phase arrest marker Cyclin B1 in Huh7 and HepG2 cells (*p<0.05, **p<0.01, ***p<0.001).

Article Snippet: Reagents used in this study included genistein (purity 99 %; catalog number G6649, Sigma-Aldrich, United States), dimethyl sulfoxide (DMSO; Sigma-Aldrich, United States), and antibodies against PCNA (catalog number 10205-2-AP, diluted 1:3,000 with Beyotime QuickBlock Western blocking buffer), Cyclin B1 (catalog number 28603-1-AP, diluted 1:3,000 with Beyotime QuickBlock Western blocking buffer), and Actin (catalog number 20536-1-AP, diluted 1:3,000 with Beyotime QuickBlock Western blocking buffer) from Proteintech Group (United States).

Techniques: In Vitro, Concentration Assay, Expressing, Marker

Figure 6: In vivo inhibition of malignant proliferation of HCC by genistein. (A) Tumor volume in mice after treatment. (B) Tumor weight in mice after treatment. (C) Photographs of tumors in mice after treatment. (D) Western Blot detected changes in the G2/M phase arrest marker protein Cyclin B1 in tumor tissues of mice after treatment (*p<0.05, ***p<0.001).

Journal: Oncologie

Article Title: Exploring the mechanism of genistein in treating hepatocellular carcinoma through network pharmacology and molecular docking

doi: 10.1515/oncologie-2024-0304

Figure Lengend Snippet: Figure 6: In vivo inhibition of malignant proliferation of HCC by genistein. (A) Tumor volume in mice after treatment. (B) Tumor weight in mice after treatment. (C) Photographs of tumors in mice after treatment. (D) Western Blot detected changes in the G2/M phase arrest marker protein Cyclin B1 in tumor tissues of mice after treatment (*p<0.05, ***p<0.001).

Article Snippet: Reagents used in this study included genistein (purity 99 %; catalog number G6649, Sigma-Aldrich, United States), dimethyl sulfoxide (DMSO; Sigma-Aldrich, United States), and antibodies against PCNA (catalog number 10205-2-AP, diluted 1:3,000 with Beyotime QuickBlock Western blocking buffer), Cyclin B1 (catalog number 28603-1-AP, diluted 1:3,000 with Beyotime QuickBlock Western blocking buffer), and Actin (catalog number 20536-1-AP, diluted 1:3,000 with Beyotime QuickBlock Western blocking buffer) from Proteintech Group (United States).

Techniques: In Vivo, Inhibition, Western Blot, Marker